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ABSTRACT 
CM-DiI and MCF-7 Breast Cancer Cell Responses to Chemotherapeutic Agents 
 CM-DiI is a lipophilic, red fluorescent dye used for staining and tracking the 
migration of cells.  CM-DiI makes it possible to visualize cells in histological regions and 
can therefore be very useful for the tracking of cancer cell proliferation and metastasis in 
vivo.  The ability to track and quantitate cancer cell proliferation in vivo is essential for 
cancer drug discovery.  If CM-DiI labeled cancer cells respond to chemotherapy agents 
similar to unlabeled cancer cells, it facilitates screening of potential anti-cancer 
compounds using CM-DiI labeled cells in a xenotransplanted, transgenic zebrafish model 
(Danio rerio).  To investigate whether CM-DiI labeling would affect cancer cells’ 
sensitivity when treated with established chemotherapeutic agents, the human breast 
cancer cell line MCF-7 was used.  The chemotherapeutic agents used were doxorubicin, 
4-hydroxytamoxifen, and paclitaxel.  We hypothesized that CM-DiI would have no effect 
on the cells’ viability and sensitivity when treated with the chemotherapeutic drugs.  Both 
labeled and unlabeled MCF-7 cells were seeded and after 24 hours each plate was treated 
with one of ten concentrations ranging from 0.05 µM to 1 mM of a chemotherapy 
compound.  After incubating for 72 hours, cell viability was determined using a 
colorimetric MTS assay.  Cell viability was not significantly different between labeled 
and unlabeled cells following exposure to doxorubicin and 4-hydroxytamoxifen.  The 
results for paclitaxel, however, were inconclusive.  These results provided evidence to 
support future aims wherein CM-DiI stained breast cancer cells will be injected into 
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transparent zebrafish that possess green fluorescent protein labeled vasculature enabling 
the tracking of cells’ growth and migration while in the presence of potential new anti-
cancer drugs. 
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1. INTRODUCTION 
 
1.1 Breast cancer 
Breast cancer is the second most common cancer in American women, and about 
40,610 women in the United States were expected to die in 2017 due to breast cancer 
(Breastcancer.org 2017).  According to the CDC, whites in the United States had an 
incidence rate of 29.8 per 100,000 for in situ (non-invasive) breast cancer and blacks had 
an incidence rate of 31.8 per 100,000 in 2014 (Centers for Disease Control and 
Prevention 2014).  The death rate for in situ breast cancer is low at roughly 3.3% overall, 
but African American women and women (of all races) under the age of 35 years may be 
at an increased risk of dying from in situ breast cancer (National Cancer Institute 2016).  
The statistics are an approximately 7% death rate for blacks with in situ breast cancer vs a 
3% death rate for whites, and a 7.8% death rate for women under the age of 35 (all races) 
vs. a 3.2% death rate for older women (National Cancer Institute 2016).  Because the 
likelihood of premature death from in situ breast cancer for African American women is 
about double that of whites, and Mississippi has the largest percent of African Americans 
of any state in the country, it is important to study cancers that greatly affect our state’s 
population (BlackDemographics.com 2018). 
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1.2 Aims 
 An overall goal of the Willett laboratory is to use a combination of in vitro and in 
vivo breast cancer models to identify new, more effective breast cancer therapeutics.  A 
fundamental requirement of xenotransplantation studies is that the cells used are similarly 
susceptible to cancer drugs.  The aim of this study was therefore to establish whether the 
red, fluorescent dye CM-DiI would affect MCF-7 breast cancer cells’ responses to three 
common chemotherapeutic agents.  If labeling cells did not affect breast cancer 
susceptibility, CM-DiI cells can be used in further xenotransplantation experiments 
involving a transparent zebrafish model (Danio rerio).  Zebrafish have become a very 
popular model organism because of their high fecundity, fast development, and 
transparency during development (Roel, 2016).  The casper;fli  line that will be 
ultimately used in these experiments also expresses GFP (green fluorescent protein) in its 
vasculature which makes it possible to track the red fluorescent cancer cell movement 
throughout the fish.  Ultimately, the CM-DiI labeled cancer cells are microinjected into 
the yolk sac of young zebrafish, prospective cancer treatments are applied, and 
microscopy is used to evaluate the growth, size, migration, metastasis, etc. of the cancer 
cells to evaluate efficacy of the treatments. 
 
1.3 MCF-7 human adenocarcinoma cells 
MCF-7 cells (shown in Figure 1) represent the most studied human breast cancer 
cell line used in research around the world.  It is named after the Michigan Cancer 
Foundation (MCF) where the cell line was established in 1973.  This cell line is one of 
3 
 
	
 
few able to produce a substantial amount of ER (estrogen receptor) which gives it the 
ability to imitate breast cancers that also express ER.  The MCF-7 cell line is a non-
invasive breast cancer that has retained several characteristics distinctive of the mammary 
epithelium, including the expression of the estrogen receptor alpha (ER) and progesterone 
receptor (PR), meaning that these cells have receptors for both hormones that could 
promote the growth of cancer (mcf7.com 2017).  The MCF-7 cell line is significant in 
research because 80% of breast cancers are estrogen receptor positive and 65% of 
estrogen receptor positive breast cancers are also progesterone receptor positive 
(Breastcancer.org 2017).  
 
Figure 1: MCF-7 human adenocarcinoma cells labeled with CM-DiI, bright field image 
taken at 10x magnification. 
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1.4 CM-DiI 
CM-DiI stands for chloromethyl-benzamidodialkylcarbocyanine and is a 
lipophilic fluorochrome used for tracking the migration of cells in vivo.  CM-DiI works 
by intercalating in the plasma membrane of a cell and then is maintained in daughter cells 
for several generations.  CM-DiI is also reported as having increased water solubility 
which makes it possible to detect marked cells in histological regions (Andrade et al. 
1996).  The red excitation/emission spectra for this dye is 553/570 nm which is ideal for 
multiplexing with green fluorescent dyes and proteins, such as GFP (green fluorescent 
protein) found in transgenic zebrafish expressing GFP (Thermofisher.com 2017).  These 
labeled cells (shown in Figure 2) enable researchers to differentiate red cancer cells vs. 
green zebrafish cells using fluorescent microscopy, allowing for easier examination of 
cancer cell proliferation within the zebrafish after microinjection.  
 
Figure 2: Fluorescing MCF-7 human adenocarcinoma cells labeled with CM-DiI under 
10x magnification under the green excitation fluorescence filter at 570 nm 
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So far there are no known effects from CM-DiI on cell viability or proliferation, 
but there are very few studies testing the effects of this dye on cell lines in conjunction 
with chemotherapy.  If the cell viability and proliferation of breast cancer cells labeled 
with CM-DiI are not significantly different from unlabeled breast cancer cells after both 
CM-DiI labeled and unlabeled cells have been treated with chemotherapy agents, it 
should be possible to examine CM-DiI labeled breast cancer cells in zebrafish using 
microscopy.  It would then be possible to conduct further research to treat these CM-DiI 
labeled breast cancers in zebrafish with new chemotherapeutic compounds and to 
examine the effects of these chemotherapeutic agents through microscopy.  
The process of transplanting cells of one species into the tissues of another 
species is known as xenotransplantation.  The xenotransplantation of CM-DiI labeled 
MCF-7 cells into zebrafish was done through the microinjection of the CM-DiI labeled 
cells into the yolk sacs of 2 dpf (2 days post-fertilization) zebrafish, and then maintaining 
the fish at 35 degrees Celsius to promote cell proliferation (Roel, 2016).  
 
1.5 Doxorubicin in cancer therapy 
Doxorubicin (DOX) is a chemotherapeutic agent belonging to the drug class of 
anthracyclines which are derived from bacteria of the genus Streptomyces (Patel et al. 
2012).  DOX works by helping to stabilize complexes of DNA and the enzyme 
topoisomerase II.  Topoisomerase II is critical for DNA replication because it has the 
ability to cut both stands of DNA to relax positive supercoils (in the presence of ATP) by 
introducing negative supercoils (Patel et al. 2012).  Although the complete mechanism of 
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action for DOX is still highly controversial, according to researchers from the Fred 
Hutchinson Cancer Research Center in Seattle, Washington, the entrapment of the 
topoisomerase II cuts the double stranded genetic material, and causes or worsens 
torsional strain, exposing DNA to damaging agents such as ROS (reactive oxygen 
species).  Such damage to a cell’s DNA results in cell death (Yang et al. 2013).    
DOX (shown in Figure 3) is one of the most commonly used drugs for adjuvant 
and neoadjuvant chemotherapy, but patients experience several common side effects of 
DOX treatment such as hair loss, pain at the site of administration, and nausea (American 
Cancer Society 2017; Micromedex 2017b).  
 
Figure 3: Chemical structure of doxorubicin, CAS Number: 25316-40-9 (Doxorubicin 
hydrochloride, Sigma-Aldrich) 
The normal dosing for DOX is 60 mg/m2 IV bolus on day 1 of each 21 day cycle 
in combination with cyclophosphamide for 4 cycles for in situ breast cancer (Pfizer Labs 
2013).  Serious side effects of DOX include premature menopause in females, infertility 
in males and chromosomal damage in sperm, fetal harm, red urine 1 or 2 days following 
the administration of the compound, and congestive heart failure.  There is also a number 
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of drug interactions for DOX including the administration of live vaccines, warfarin, 
paclitaxel, grapefruit juice, and quinidine (Micromedex 2018b).  Patients of reproductive 
age should be advised to use a suitable form of birth control during therapy of DOX and 
for 6 months following discontinuation of DOX due to adverse effects DOX can have on 
a fetus.  Health professionals are generally advised to tell patients to consult a doctor or 
pharmacist before using a new drug due to the many drug interactions with DOX.  This 
would include over-the-counter medications, vitamins, and herbal supplements (Pfizer 
Labs 2013).  
 
1.6 4-Hydroxytamoxifen in cancer therapy 
4-Hydroxytamoxifen (4-OHT) (shown in Figure 4) is a metabolite of tamoxifen 
(TAM) and has a high affinity for estrogen receptors (ERs) due to the similarity of its 
structure to estradiol.  In breast tissue, 4-OHT competes with estrogens as an antagonist 
for ERs.  Estrogens have proliferative influence in ER+ cells such as MCF-7.  The ERs 
are capable of stimulating cancer growth by binding to elements in certain genes’ 
promoters and by activating growth factors and pro-survival kinases.  Therefore, by 
blocking estrogen from binding to estrogen receptors, 4-OHT blocks the ER’s cancer 
promoting activity (Pawlik et al. 2016). 
4-Hydroxytamoxifen is one of the active metabolites of the prodrug tamoxifen 
and is not normally given to breast cancer patients as therapy unless they suffer from 
liver disease, other hepatic impairments (where the drug is metabolized), or if a patient is 
a poor metabolizer (PM) of the cytochrome P450 enzyme CYP2D6 (Maximov et. al, 
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2014; Whitfield, et al., 2015).  Existing clinical and laboratory data support a hypothesis 
that 4-OHT could show increased efficacy and perhaps require lower doses than TAM in 
these patients, along with a reduced occurrence of adverse effects.  4-OHT has poor oral 
bioavailability due to first-pass metabolism, and so 4-OHT is being developed as a 
topical gel undergoing Phase II clinical trials (as of 2015) (Zhong et. al, 2015). 
 
Figure 4: Chemical structure of 4-hydroxytamoxifen, CAS Number: 68392-35-8 (4-
hydroxytamoxifen, Sigma Aldrich) 
 
1.7 Paclitaxel in cancer therapy 
Paclitaxel (TAX) (shown in Figure 5) is a chemotherapeutic drug used to kill 
cancer cells by microtubule stabilization.  Microtubules are used in the separation of 
chromosomes during cell division, and then disassemble to allow the formation of two 
new daughter cells.  When cells are treated with TAX, the stabilization of the 
microtubules restricts the disassembly of microtubules and prevents the formation of 
daughter cells.  This paclitaxel-induced mitotic arrest causes the cell to undergo apoptosis 
because it can no longer pass the spindle assembly checkpoint (Weaver 2014). 
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Paclitaxel is a commonly used chemotherapeutic agent for the treatment of breast 
cancer, and patients experience many of the commonly known side effects such as 
nausea, mouth sores, and hair loss.  After a standard doxorubicin-containing regimen, 
paclitaxel is normally administered at a dose of 175 mg/m2 through IV over 3 hours every 
3 weeks for 4 courses (given following doxorubicin-containing chemotherapy) 
(Micromedex 2018).  Prior to this administration, however, the patient should medicate 
beforehand with 20 mg dexamethasone orally at about 12 and 6 hours prior to paclitaxel 
administration, as well as 50 mg diphenhydramine (Benadryl) intravenously, and either 
300 mg cimetidine (Tagamet) or 50 mg ranitidine (Zantac) intravenously 30 to 60 
minutes before paclitaxel administration.  These medications are taken to decrease the 
severity of the hypersensitivity reactions to paclitaxel (Micromedex 2018; Quock, et al. 
2002).  
 
Figure 5: Chemical structure of paclitaxel, CAS Number: 33069-62-4 (Paclitaxel, Sigma 
Aldrich) 
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1.8 MTS viability assay 
The MTS assay is a colorimetric method for quantification of viable cells in 
proliferation.  The assay involves the reduction of the tetrazolium compound in MTS [(3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium] by viable cells, and the electron coupling reagent PMS (phenazine 
methosulfate) also needed for the reaction.  The reduction is accomplished by 
dehydrogenase enzymes in viable cells, and it causes the formation of a colored formazan 
product which is soluble in cell culture media.  The formazan product produced only by 
viable cells can then be quantified by measuring the absorbance at 490-500 nm 
(Abcam.com 2017). 
 
1.9 Hypothesis 
The hypothesis for this experiment was the IC50 concentrations of decreased cell 
viability would not significantly differ between CM-DiI labeled and unlabeled MCF-7 
cells following treatment with established chemotherapy drugs (doxorubicin, 4-
hydroxytamoxifen, and paclitaxel).  In other words, the dye CM-DiI would have no effect 
on the IC50 concentrations for doxorubicin, 4-hydroxytamoxifen, or paclitaxel.  The IC50 
is the concentration of a compound required to reduce viability of 50% of cells in culture 
(Lyles, 2008).  
 
 
11 
 
	
 
 
 
2. MATERIALS AND METHODS 
 
2.1 Cell culture 
The MCF-7 cell line was maintained according to ATCC guidelines (American 
Type Culture Collection, located in Manassas, VA).  MCF-7 cells were placed in 
Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine 
serum (FBS) and 1% penicillin/streptomycin antibiotics (P/S) at 37 degrees Celsius 
(average normal body temperature) in humid conditions with 5% carbon dioxide.  These 
cells were maintained in an exponential growth state, not overgrown or senescent, until 
needed for procedures (American Type Culture Collection).   
Passages occurred roughly twice a week in order to keep cell confluency between 
30% and 90%.  To passage, 2-3 mL of 0.25% Trypsin-0.53 mM EDTA (ethylenediamine 
tetraacetic acid) solution was first added to the flask to detach the cell layer.  The flask 
was then placed in a shaking incubator for no more than 5 minutes to ensure the cells had 
detached from the flask.  The flask was next washed with 4-5 mL of media (DMEM as 
described above) to neutralize the trypsin enzyme and then centrifuged at 4000 rpm for 5 
minutes.  The media/trypsin mixture was poured off, and 4-5 mL of fresh media was used 
to break up the cell pellet in the bottom of the tube.  A cell counter was used to quantitate 
the number of cells/mL and the stock was subsequently diluted to maintain cell 
confluency. 
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2.2 Cell labeling and plating 
Cells were labeled according to the manufacturer’s (Thermo Fisher Scientific) 
instructions.  The stock solution of CM-DiI was made by adding 25 µL of DMSO 
(dimethyl sulfoxide) to 50 µg of CM-DiI.  About 1 x 107 cells were suspended in 1 mL 
phosphate buffered saline (PBS) with 2 µL of CM-DiI cell labeling solution to make a 5 
µM working solution.  Although only 3.4 x 105 cells were needed per plate for testing, 
more cells were needed to go through the labeling protocol due to cell death during the 
labeling process.  The cells in the working CM-DiI/PBS solution were next placed in an 
incubator at 37 degrees Celsius for five minutes and then in a refrigerator at 4 degrees 
Celsius for 15 minutes.  After labeling, the cells were washed with PBS and resuspended 
in a milliliter of their appropriate media (DMEM supplemented with 10% fetal bovine 
serum (FBS) and 1% penicillin/streptomycin antibiotics (P/S)).  The cells labeled with 
CM-DiI were plated in 60 wells of a 96-well plate with 90 µL of cell solution per well, a 
cell density of 5,000 cells per well, and a total of 3.4 x 105 cells per plate.  Cells not 
labeled with CM-DiI were also plated in the same manner, and both cell plates were then 
placed in an incubator at 37 degrees Celsius to allow the cells to attach overnight.  
 
2.3 Drug treatment  
A 10-concentration drug plate was made the day following cell plating.  This drug 
plate was made by diluting drugs 1:3 for a range of 0.05 µM to 1 mM (0.05 µM, 0.15 
µM, 0.46 µM, 1.4 µM, 4 µM, 12 µM, 37 µM, 111 µM, 333 µM, 1 mM).  Next 10 µL of 
each drug concentration were added to corresponding wells of the CM-DiI labeled and 
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unlabeled cell plates (each well containing 90 µL of cell solution), and the cells were 
incubated at 37 degrees Celsius untouched for 72 hours.  Therefore, the final 
concentration in the cell treatments ranged from 0.005 (~0) µM to 100 µM. 
 
2.4 MTS assay 
At the end of the 72-hour incubation period, 20 µL of 2 mg/2 mL MTS and 5% 
PMS were added to each well of each plate.  Next, the plates were incubated at 37 
degrees Celsius for 2-4 hours.  At the end of 2-4 hours, absorbance was read on a Bio-
Tek spectrophotometer at 490 nm.  In this study, the absorbance was read most often at 
the end of 4 hours.  If the plates were read too early, the cells did not have time to take up 
the PMS (electron carrier), and if the plates were read too late the plates appeared dark 
brown and were too difficult to read.  
 
2.5 Statistical analysis 
Each drug experiment had internal biological triplicate replicates and, using 
GraphPad Prism Version 5.0, non-linear regression analysis was used to determine the 
IC50’s for each compound.  This was done by using non-linear regression analysis with 
curve-fit and using the dose response-inhibition equation (log[inhibitor] vs. response) 
with variable slope.  Unknown values were interpolated from the standard curve with a 
95% confidence interval.  The IC50 values for labeled and unlabeled cells for both 
doxorubicin and 4-hydroxytamoxifen were tested for significance using GraphPad Prism 
5.0 as well.  A two-tailed, unpaired t-test with Welch’s correction of not assuming equal 
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variances was done for each set of IC50’s (doxorubicin and 4-hydroxytamoxifen) at a 
95% confidence interval.  
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3. RESULTS AND DISCUSSION 
 
The IC50 for doxorubicin (DOX) was found to be 0.33 ± 0.041 µM for the CM-
DiI labeled MCF-7 cells and 0.47 ± 0.038 µM for the unlabeled cells in this experiment 
(Figure 6).  An unpaired t-test with Welch’s corrections found the IC50 for DOX treated 
MCF-7 cells to not be significantly different with a p-value equal to 0.0578.  The IC50 
found for CM-DiI labeled cells treated with 4-hydroxytamoxifen (4-OHT) was 27.48 ± 
0.52 µM and for unlabeled MCF-7 cells the IC50 was found to be 28.80 ± 0.71 µM 
(Figure 7).  Another unpaired t-test with Welch’s corrections found the IC50 for 4-OHT 
treated MCF-7 cells to not be significantly different with a p-value equal to 0.2288.  The 
IC50’s for doxorubicin can be visualized in the Figure 6 and the IC50’s for 4-
hydroxytamoxifen can be visualized in Figure 7, both of which logarithmically graph the 
drug concentrations versus time.  For 4-hydroxytamoxifen, there was a very steep 
decrease in viability between the concentrations 11.1 µM and 33.3 µM.  Future studies 
should expand the dose range between these concentrations.  The results after treatment 
of MCF-7s with paclitaxel were inconclusive, and further work for this drug will be 
needed.    
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Figure 6: Doxorubicin concentration comparison for CM-DiI labeled (dye) and 
unlabeled (no dye) MCF-7 adenocarcinoma cells. 
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Figure 7: 4-hydroxytamoxifen concentration comparison for CM-DiI labeled (dye) and 
unlabeled (no dye) MCF-7 adenocarcinoma cells. 
 
Difficulties arose when it was found that after a few experiments with paclitaxel 
cell counts began differing between the CM-DiI labeled and unlabeled cell plates.  At the 
end of a few experiments, we evaluated the cells in the wells of the plates using 
microscopy and found that the CM-DiI labeled cell plates had a much lower number of 
viable cells than the unlabeled cell plates.  We then hypothesized that during the labeling 
process cells were dying not only due to the intercalation of CM-DiI into the cellular 
membranes, but the cell washings with PBS as well (Andrade et. al, 1996).  To prevent 
the faltering numbers of labeled MCF-7 cells from affecting the cell viability assays, a 
greater number of cells was needed to undergo the labeling process so that the correct 
number of cells could be plated. Under the advice given from an advisor, about 100 times 
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the number of cells needed were used to undergo the labeling process (107 vs. 6.8 x 105 
cells for two plates).  After the cells were labeled, they were counted again (count was 
given in cells/mL) and the appropriate number of cells (3.4 x 105 cells per 6mL plate) 
was used.  The remainder of the labeled cells was passaged into a new flask. 
Even after accounting for the cell death during the labeling process, the MTS 
assay for TAX continued to prove difficult.  Sometimes the 4-hour incubation time 
appeared to be too long and the plates were too dark to read.  This was the only 
compound, however, that was problematic with the 4-hour incubation time-period.  
Eventually, no further testing could be done to resolve this issue as resources began to 
diminish.  
Three different classes of chemotherapy drugs were used in this study to test 
whether the use of a lipophilic dye, CM-DiI, would have any effect on drugs’ IC50 when 
used to treat a breast cancer cell line, MCF-7, labeled with CM-DiI. The three classes 
used, anthracyclines, selective estrogen receptor modulators (SERMs), and taxanes, were 
represented by doxorubicin (DOX), 4-hydroxytamoxifen (4-OHT), and paclitaxel (TAX), 
respectively.  The IC50’s found in this study were compared to other cancer drugs from 
the literature using the cancer cell line MCF-7 and were then compared to results found 
in different cancer cell lines using the same drugs.  
Epirubicin is a member of the anthracycline class and is an epimer of doxorubicin. 
Epirubicin differs in the orientation of a hydroxyl group on the sugar, and because of this 
change is less cardiotoxic than doxorubicin (Anthracyclines 2017).  Doxorubicin, 
however, is more effective in the treatment of the breast cancer cell line, MCF-7, than 
epirubicin.  The IC50 for DOX (no CM-DiI) was found in this study to be 0.0.47 ± 0.038 
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µM, while the IC50 for epirubicin according to a study conducted by the Department of 
Oncology in Weifang Traditional Chinese Hospital was 13 ± 1.4 µM (Sun et al. 2015). 
Another member of the anthracycline class is daunorubicin, which was the first 
anthracycline compound to be characterized structurally.  It is normally used in the 
treatment of lymphoblastic and myeloblastic leukemias (Anthracyclines 2017). 
Daunorubicin’s IC50 according to a study conducted at the University of Alberta was 5.5 
± 0.5 µM, and greater than the IC50 found for DOX (Shi et al. 2010).  Therefore, DOX 
appears to be more cytotoxic in MCF-7 cells than either daunorubicin or epirubicin. 
 
Table 1: IC50 in MCF-7 cells for drugs in anthracycline drug class. 
Anthracyclines  IC50  Reference 
Doxorubicin 0.47 ± 0.038 µM This study 
Epirubicin 13 ± 1.4 µM Sun et al. 
Daunorubicin 5.5 ± 0.5 µM Shi et al. 
 
Among the selective estrogen receptor modulators (SERMs), tamoxifen (TAM) is 
a first-generation breast cancer treatment and is prescribed to treat estrogen receptor 
positive (ER+) breast cancers.  TAM is converted to 4-OHT by enzymes found in the 
liver, therefore, in patients with liver problems who are unable or have decreased ability 
to perform the conversion of TAM to 4-OHT, the administration of 4-OHT is often 
preferred (Whitfield et al. 2015).  TAM, however, is more effective than 4-OHT in the 
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treatment of the breast cancer cell line MCF-7 with an IC50 of 10 µM (Badal et al. 2017), 
compared to 4-OHT’s IC50 (no CM-DiI) found in this study, 28.80 ± 0.71 µM. 
Raloxifene is another member of the SERM class and is a nonsteroidal 
benzothiophene.  Studies have reported that raloxifene produces estrogen-agonist effects 
on bone metabolism, but estrogen-antagonistic effects on uterine and breast tissue (Tu et 
al. 2012).  Therefore, it is effective in preventing osteoporosis and in the prevention of 
breast cancer without the side effect of uterine adenocarcinoma development, which is a 
side effect of tamoxifen (Tu et al. 2012).  Studies are in conflict as to whether raloxifene 
or tamoxifen is more effective in treating breast cancer.  In one study performed by Dr. 
Martinkovich and his colleagues, it appeared that raloxifene and tamoxifen were equally 
effective over a 5-year period, but tamoxifen was more effective than raloxifene over an 
81-month period (Martinkovich et al. 2014).  The IC50 of raloxifene in MCF-7 cells, 
however, is lower than tamoxifen (as well as 4-hydroxytamoxifen) with a value of 0.025 
µM (Okamoto et al. 2008).  
Tamoxifen is the most commonly prescribed therapy to treat breast cancer and 
was supposed to be used in this study.  While working on this project there was a limited 
supply of TAM available for use, therefore, its metabolite 4-OHT was solely tested 
instead.   
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Table 2: IC50 in MCF-7 cells for drugs in the SERM drug class. 
SERMs IC50 Reference 
4-hydroxytamoxifen 28.80 ± 0.71 µM This study 
Tamoxifen 10 µM Badal et al. 
Raloxifene 0.025 µM Okamoto et al. 
 
Although difficulties arose when treating the MCF-7s with paclitaxel (TAX) and 
further work will be needed, its use in this study is important as it is often used in 
combination with DOX for managing breast cancer (Micromedex, Adult Dosing, 2018).  
Many types of breast cancers are also now resistant to TAX, so newer compounds are 
needed to combat this resistance (Ajabnoor et al. 2012). 
Doxorubicin (DOX), 4-hydroxytamoxifen (4-OHT), and paclitaxel (TAX) are not 
always used in the treatment of breast cancers.  For example, DOX can be used in the 
treatment of prostate and neurofibroblastomas as well.  Although these cell lines were not 
examined in this study, it is important to compare the drugs’ efficacies in breast cancer to 
other types and lines of cancers.  
For example, DOX’s IC50 values when used to treat the prostate cancer cell line 
PC3 and the neurofibroblastoma cell line UKF-NB-4 (0.91 µM and 0.7 µM respectively) 
(Poljaková et al. 2008) were higher than the IC50 value for DOX when used to treat the 
breast cancer cell line MCF-7 (0.47 ± 0.038 µM).  DOX’s IC50 value for the prostate 
cancer cell line DU145, however, is 0.343 µM suggesting that DOX is more effective in 
the treatment of that specific type of prostate cancer (Tsakalozou et al. 2012). 
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Table 3: IC50’s in different cell types for doxorucbicin. 
Cell Type IC50 for DOX Reference 
MCF-7 0.47 ± 0.038 µM This study  
PC3 0.91 µM Poljaková et al.  
UKF-NB-4 0.7 µM Poljaková et al.  
DU145 0.343 µM Tsakalozou et al.  
 
The use of 4-OHT is used almost exclusively for breast cancer, and studies 
involving 4-OHT and other types of cancer cell lines are scarce.  4-OHT’s efficacy is 
dependent, however, on the different types of breast cancers.  T47D is a breast cancer cell 
line that is also estrogen-receptor positive (ER+), but T47D cells are a ductal carcinoma 
cell line, while MCF-7 cells are an adenocarcinoma cell line (Mooney et al. 2002).  BT-
474 is another ER+ breast cancer, but it is characterized by the overexpression of human 
epidermal growth factor receptors 2 (HER-2) as well as ER (Washington Biotechnology 
2014).  The IC50 values for 4-OHT in T47D and BT-474 cells were 4.2 µM and 5.7 µM, 
respectively, according to a study conducted by scientists at the University of Gdańsk in 
Poland (Pawlik et al. 2015).  This suggests that 4-OHT may not be as effective in the 
treatment of MCF-7 cells when comparing to the 28.80 ± 0.71 µM IC50 found in this 
study.  According to the study conducted by scientists at the University of Gdańsk, 
however, the IC50 for 4-OHT when treating MCF-7 cells was 3.2 µM (Pawlik et al. 
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2015).  Because this value is lower than the IC50 values for T47D and BT-474 cells, that 
study suggests that 4-OHT is indeed more effective when treating MCF-7 cells.  
Unfortunately, our study did not use T47D or BT-474 cells in order to compare whether 
or not the IC50 found would show 4-OHT to be more effective in MCF-7 cells as well.  
The decision to use MCF-7 cells stemmed from the fact that MCF-7 cells are the most 
commonly used breast cancer cells in research.  To eventually establish a model system 
in transparent zebrafish, it was important to test the most commonly used breast cancer 
cells.  
 
Table 4: IC50’s in different cell types for 4-hydroxytamoxifen. 
Cell Type IC50 for 4-OHT Reference 
MCF-7 28.80 ± 0.71 µM This study 
T47D 4.2 µM Pawlik et al. 2015 
BT-474 5.7 µM Pawlik et al. 2015 
 
In conclusion, labeling with CM-DiI did not significantly impact the viability of 
the MCF-7 breast cancer cells treated with DOX or 4-OHT. Future work, however, is 
needed to optimize the exposures with TAX.  
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